Response: Data submission specifications for the reporting of this measure are available in the Hospital OQR Program Specifications Manual and would have applied to the ASCQR Program if the measure had been adopted as proposed
While Retatrutide has generated significant excitement in obesity medicine due to encouraging clinical trial results, it remains an investigational medication that is currently in Phase 3 clinical trials and has not yet received FDA approval
These injections help people feel full quicker, eat less, and lose weight within weeks

Strategic Product Launch: Revenue Generation : Peptide Pen line adds new product category to CELLGENIC's portfolio, distributed through RMTG's global network spanning 30+ countries Market Positioning : Pre-loaded synergistic formulations address growing demand for convenient peptide therapy solutions in regenerative and longevity medicine Distribution Advantage : Exclusive sales to licensed physicians through established RMTG affiliate network, including recent Brazil, Dominican Republic, and northern Argentina/Paraguay partnerships Summit Launch Platform : Global Summit presentation generated immediate physician interest and orders from international attendees representing 30+ countries Product Line Expansion : Peptide Pens complement existing CELLGENIC portfolio including exosomes, MSCs, and platelet-rich plasma kits, increasing average order value Educational Integration : ISSCA training programs incorporate peptide therapy protocols, driving product adoption through certification workshops and physician education "We are thrilled with GSCG's launch of CELLGENIC's innovative Peptide Pen product line, which represents a groundbreaking advancement in regenerative medicine," said David Christensen, CEO of RMTG

Outcome findings from pairwise meta-analysis The pooled SMDs for overall pain assessment between treatments versus the control group was -0.33 (95% CI: -0.52, -0.14)